Sex-specific role of microglia in Δ9-tetrahydrocannabinol-induced disruption of fear memory reconsolidation
In PTSD, microglia are more engaged in fear-related circuits, where they participate in fear memory processing responses. The reconsolidation-impairing effect of Δ⁹-tetrahydrocannabinol (THC), the primary psychoactive constituent of Cannabis, is typically linked to cannabinoid type-1 receptor (CB1) signaling. THC also engages peroxisome proliferator-activated receptor gamma (PPARγ), and both CB1 and PPARγ modulate neuroimmune processes, including microglial activity. This dual mechanism suggests that THC's impact on fear memory reconsolidation may extend beyond classical cannabinoid signaling. We hypothesize that THC disrupts contextual fear memory reconsolidation via microglial recruitment in the dorsal hippocampus (DH) through a sex-specific engagement of CB1 and PPARγ. Adult male and female Wistar rats underwent contextual fear conditioning, followed by THC (0.002 mg/kg, i.p.) or vehicle administration immediately after memory retrieval. Microglial involvement was assessed using immunofluorescence and pharmacological and chemogenetic inhibition in DH. The role of CB1 and PPARγ receptors was assessed via intra-DH selective antagonist infusion. THC impaired reconsolidation in males and females. In males, fear memory retrieval increased microglial engagement in the DH CA1 subfield, which THC further enhanced. Pharmacological and chemogenetic inhibition of microglia, as well as selective CB1 and PPARγ antagonism, blocked THC's effects in males. In females, THC-induced reconsolidation blockade was cycle-dependent, occurring at estrus and diestrus but not at proestrus, and was mediated exclusively through CB1 activation. These findings identified sex-specific neuroimmune pathways mediating THC's reconsolidation impairment, offering a mechanistic basis for novel sex-tailored therapeutic opportunities.
Authors
- Graziano Pinna (ORCID: https://orcid.org/0000-0001-7541-4855)
- Cristina Aparecida Jark Stern (ORCID: https://orcid.org/0000-0002-1736-5503)
- Erika Meyer (ORCID: https://orcid.org/0000-0002-8425-6358)
- Nathalie Carla Cardoso (ORCID: https://orcid.org/0000-0002-5681-5132)
- Ana Maria Raymundi (ORCID: https://orcid.org/0000-0002-8012-4104)
- Leandro J. Bertoglio (ORCID: https://orcid.org/0000-0003-2876-1146)
- Francisco Silveira Guimarães (ORCID: https://orcid.org/0000-0003-4092-7778)
- Ruliam Queiroz (ORCID: https://orcid.org/0000-0003-0402-3886)
- Luciano Vitali (ORCID: https://orcid.org/0000-0002-1664-6346)
- Gabriel Costa Lourenço
- Sabrina Francesca Lisboa (ORCID: https://orcid.org/0000-0002-2069-3524)
- Maressa D. Dolzan
Institutions
- Illinois College (US)
- Universidade de São Paulo (BR)
- University of Illinois Chicago (US)
- Universidade Federal de Santa Catarina (BR)
- Instituto Federal de Educação, Ciência e Tecnologia de Santa Catarina (BR)
- Universidade Federal do Paraná (BR)
Publication Details
- Journal
- Neuropsychopharmacology
- Published
- 2026-05-09
- DOI
- https://doi.org/10.1038/s41386-026-02434-x
- Primary Topic
- Cannabis and Cannabinoid Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Fundação de Amparo à Pesquisa do Estado de São Paulo
- Coordenação de Aperfeiçoamento de Pessoal de Nível Superior
- Conselho Nacional de Desenvolvimento Científico e Tecnológico
- Fundação Araucária
- Financiadora de Estudos e Projetos
- Universidade Federal do Paraná
- National Institutes of Health